Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22025286 | 0.82 | MEN1 (0.34) | FAAHMEN1KMT2A | |
| SCHEMBL21403711 | 0.81 | KMT2A (0.34) | FAAHMEN1KMT2A | |
| SCHEMBL21403608 | 0.81 | L3MBTL1 (0.32) | MEN1KMT2ADPP4 | |
| SCHEMBL10634002 | 0.81 | L3MBTL1 (0.32) | MEN1KMT2ADPP4 | |
| SCHEMBL6935567 | 0.81 | L3MBTL1 (0.32) | MEN1KMT2ADPP4 | |
| SCHEMBL21403646 | 0.80 | HDAC6 (0.31) | MEN1KMT2ADPP4 | |
| SCHEMBL25838348 | 0.79 | MEN1 (0.36) | MEN1KMT2ADPP4 | |
| SCHEMBL21403728 | 0.77 | SMN1; SMN2 (0.38) | MEN1KMT2A | |
| SCHEMBL21403730 | 0.77 | SMN1; SMN2 (0.38) | MEN1KMT2A | |
| SCHEMBL19990073 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-10851099-B2 | Dipeptide piperidine derivatives | Oncoarendi Therapeutics S.A. (PL) | 2020-12-01 | — | — | US | disclosed |
| WO-2019186497-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | US | disclosed |
| US-9375497-B2 | [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851099-B2 | Dipeptide piperidine derivatives | ARG1, ARG2, PEPD | FAAH 2284/4885MEN1 4352/4885KMT2A 2932/4885 |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | ARG1, ARG2, PEPD | FAAH 2284/4885MEN1 4352/4885KMT2A 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.